CHUGAI PHARMACEUTICAL : and Novartis Pharma to Terminate Co-Marketing Agreement of Aromatase Inhibitor “Femara® Tablets 2.5 mg,” a Treatment for Breast Cancer after Menopause

TOKYO, January 6, 2016 - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Chugai and Novartis Pharma K.K. have agreed to terminate the agreement regarding co-marketing of aromatase inhibitor 'Femara tablets 2.5 mg' (generic name: letrozole, hereafter Femara), a treatment for breast cancer after menopause in Japan, as of January 31, 2016.
Novartis Pharma will be solely responsible for the distribution and commercialization of Femara in Japan from February 1, 2016.

Chugai and Novartis Pharma will cooperate to accomplish a smooth transition. During the transition period, both companies will maintain the same level of product supply and adequate commercial activities to satisfy any medical needs.

About Femara Tablets 2.5 mg

Generic Name:	Letrozole
Brand Name:	Femara Tablets 2.5 mg
Approval Date:	January 23, 2006
Launch Date:	May 11, 2006
Indication:	Breast cancer after menopause
Dosage and administration:	The usual adult dosage is 2.5 mg administered orally once daily.
Drug Price:	JPY 674.1/Tablet
Manufacturer & Distributor:	Novartis Pharma K.K.
Distribution and commercialization:	Novartis Pharma K.K. (on or after February 1, 2016)

Contact:
For Media
Chugai Pharmaceutical Co., Ltd
Media Relations Group, Corporate Communications Dept.,
Koki Harada
Tel: [phone]
E-mail: [e-mail]

For Investors
Chugai Pharmaceutical Co., Ltd
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: [phone]
E-mail: [e-mail]